Trxade Health Overview
Latest ROE for Trxade Health: 230324.93% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow230324.93%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for MEDS is 230324.93%. That is above the Finance sector average of 17.11%. Investors often review this figure alongside Trxade Health's historical trend and sector peers before judging valuation or financial health.
Against Finance companies, MEDS currently prints 230324.93% for ROE, while the sector average sits near 17.11%. That is roughly 1346125.7% above the sector mean. Large gaps often invite a closer look at Trxade Health's growth, margins, and balance sheet.
Return on Equity shows how effectively Trxade Health converts resources into returns. At 230324.93%, MEDS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting MEDS's ROE (230324.93%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Trxade Health's ROE against similar Finance names. You can also browse sector and industry screens on Stockcircle for a broader set of Finance companies and their key multiples and fundamentals.
